TMCnet News
BUYINS.NET: CRB, URZ, AFFY, BWTR, CREE, ARGA Have Been Added To Naked Short List Today(M2 PressWIRE Via Thomson Dialog NewsEdge) RDATE:04062007 BUYINS.NET, www.buyins.net, announced today that these select companies have been added to the NASDAQ, AMEX and NYSE naked short threshold list: Courtside Acquisition Corp. (AMEX: CRB), Uranerz Energy Corporation (AMEX: URZ), Affymax Inc. (NASDAQ: AFFY), Basin Water Inc. (NASDAQ: BWTR), Cree Inc. (NASDAQ: CREE), Auriga Laboratories Inc. (OTCBB: ARGA). For a complete list of companies on the naked short list please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to www.buyins.net. Courtside Acquisition Corp. (AMEX: CRB) does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, or other similar business combination with an operating business focusing on the entertainment, media, and communications industries. The company was founded in 2005 and is based in New York, New York. With 16.80 million shares outstanding and 75,270 shares declared short as of May 2007, there is a failure to deliver in shares of CRB. Uranerz Energy Corporation (AMEX: URZ) an exploration stage company, engages in the acquisition, exploration, and development of uranium properties. It owns interests in state mineral leases and federal mining claims in Power River Basin and the Great Divide Basin in Wyoming; Cochrane River Property in Saskatchewan, Canada; and eight exploration licenses in Mongolia. The company was founded in 1999. It was formerly known as Carleton Ventures Corp. and changed its name to Uranerz Energy Corporation in 2005. Uranerz Energy Corporation is based in Vancouver, Canada. With 39.05 million shares outstanding and 1.03 million shares declared short as of May 2007, there is a failure to deliver in shares of URZ. Affymax Inc. (NASDAQ: AFFY) a biopharmaceutical company, engages in the development of peptide-based drug candidates to enhance the treatment of serious and life-threatening conditions. Its lead product candidate includes Hematide, a synthetic peptide-based erythropoiesis stimulating agent, which is designed to treat anemia associated with chronic kidney disease and cancer. The company is conducting phase II clinical trials of Hematide in dialysis patients, predialysis patients, cancer patients on chemotherapy and patients with PRCA. It is also developing a pipeline of peptide based drug candidates, including Adeptide, a peptide based, non-injectable erythropoiesis stimulating agent; the Innotide program that comprises a family of peptide based drug candidates for use in the area of tissue protection in preclinical models of stroke, myocardial infarct, and renal injury; and Angiotide, a synthetic peptide for treating cancer by blocking angiogenesis, or blood vessel formation in tumors. Affymax has strategic alliances with Takeda Pharmaceutical Company Limited to develop and commercialize Hematide; EntreMed, Inc. for preclinical research of Angiotide; and Nektar Therapeutics AL, Corporation. The company was founded in 2001 and is based in Palo Alto, California. With 14.9 million shares outstanding and 289,700 shares declared short as of May 2007, there is a failure to deliver in shares of AFFY. Basin Water Inc. (NASDAQ: BWTR) engages in the design, building, and implementation of systems for the treatment of contaminated groundwater. The company offers ion-exchange treatment system that reduces groundwater contaminant levels. Its system is installed at the site of the well to treat varying volumes of water. The company serves utilities, municipalities, special districts, real estate developers, and other organizations that supply water for use in treating groundwater sources. Basin Water markets its system through direct sales force, independent contractors, and strategic partners primarily in the United States. The company was founded in 1999 and is headquartered in Rancho Cucamonga, California. With 19.91 million shares outstanding and 3.31 million shares declared short as of May 2007, there is a failure to deliver in shares of BWTR. Cree Inc. (NASDAQ: CREE) engages in the development and manufacture of semiconductor materials and devices based on silicon carbide, gallium nitride, silicon, and related compounds. Its products include light emitting diodes (LEDs) comprising blue, green, and near ultraviolet LED chips, as well as high power packaged LEDs; power switching, radio frequency, and microwave devices; and near UV lasers. The company's LED products are electronic components used in various applications, including backlighting for mobile products and automotive interior lighting, and color electronic displays, as well as light source for gaming equipment, consumer products, and other electronic equipment. Its high power packaged LEDs are used in architectural lighting, appliance lighting, and reading lamps. The company's power switching products are applied in power factor correction circuits for power supplies in computer servers and other applications. Its radio frequency circuits are used in bandwidth communications applications, high-power radar amplifiers, electronic warfare, and wireless infrastructure. Cree, Inc. sells its products to corporate, government, and university research laboratories, as well as to customers who resale to original equipment manufacturers. The company operates in Japan, Malaysia, the United States, Hong Kong, Korea, Taiwan, and Europe. Cree, Inc. was founded in 1987 and is based in Durham, North Carolina. With 84.26 million shares outstanding and 11.85 million shares declared short as of May 2007, there is a failure to deliver in shares of CREE. Auriga Laboratories Inc. (OTCBB: ARGA) a specialty pharmaceutical company, engages in the development of pharmaceutical products for respiratory, dermatology, and psychiatry markets. The company's product line includes Aquoral, a prescription product for the treatment of xerostomia or dry mouth; Zinx for relief of symptoms associated with common cold and allergies; Extendryl for the treatment of cough, cold, and allergy symptoms; and Levall used in the treatment and relief from cough, congestion, and rhinitis associated with respiratory infections, such as the common cold, influenza, bronchitis, and sinusitis. It also offers dermatology products, such as Akurza and Xyralid. The company has product development license agreements with Athlon Pharmaceuticals and Cornerstone Biopharma. Auriga Laboratories was founded in 2005 and is based in Los Angeles, California. With 42.13 million shares outstanding and 27,900 shares declared short as of May 2007, there is a failure to deliver in shares of ARGA. About BUYINS.NET WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades. BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted, www.buyins.net/squeezetrigger.pdf. The SqueezeTrigger database of nearly 1,400,000,000 short sale transactions goes back to January 1, 2005, and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005, because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data. The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each month's short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money. All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET may receive compensation in cash or shares from independent third parties or from the companies mentioned. BUYINS.NET affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. Market commentary provided by Thomas Ronk. BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements. CONTACT: Thomas Ronk, CEO Tel: +1 800 715 9999 e-mail: [email protected] WWW: http://www.buyins.net ((M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [email protected])). Copyright 2007 M2 Communications Ltd. |